Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

FluoroPharma Inc.

Sep 2008
FluoroPharma Inc. of Boston, a developer of molecular imaging agents for the PET market, has announced successful Phase I safety results for BFPET, a fluorine-18-labeled tracer for myocardial perfusion imaging. The imaging agent analyzes blood flow in the heart and assesses coronary artery disease in patients.

BiophotonicsenergyFluoroPharma Inc.molecular imagingmyocardial perfusion imagingNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x Subscribe to BioPhotonics magazine - FREE!